Authors

Matthew Royle, Ph.D.

Partner

Read More

Dr. Manja Epping

Partner

Read More

Evelyne Friedel

Partner

Read More
Authors

Matthew Royle, Ph.D.

Partner

Read More

Dr. Manja Epping

Partner

Read More

Evelyne Friedel

Partner

Read More

10 October 2018 |

Biosimilars

Many of the top selling drugs worldwide are biologics and many companies are seeking to produce biosimilars to compete in these lucrative markets. Activity relating to biosimilars is intensifying in the US following the introduction of the BPCIA and continues in Europe since the first biosimilars were authorised in 2006. Successfully bringing a biosimilar to market raises different challenges to small molecule generics and there are differences in the approach in the US and Europe.

Taylor Wessing and Willkie Farr & Gallagher hosted a series of three webinars covering various aspects of market access for biosimilars.

Biosimilars - an overview of the route to market in the US and Europe

  • Basics of the regulatory system in the US and Europe​
  • History of approvals and launches in the US and Europe
  • Overview of the "patent dance" under the BPCIA and contrast to the position in Europe

Biosimilars - interchangeability / substitution and advertising

  • Access to market – how biosimilars are prescribed in the US, the UK, France, Germany and the Netherlands
  • Issues relating to interchangeable biosimilars in the US
  • Advertising rules in the US compared to the position in UK, France, Germany and the Netherlands​​​​

Biosimilars - pricing and reimbursement and the competitive landscape

  • Overview of the pricing and reimbursement process in the US, the UK, France, Germany and the Netherlands
  • Product launches – the line between competition and a breach of antitrust rules ​​​​


Alternatively watch the full playlist here.

Call To Action Arrow Image

Latest insights in your inbox

Subscribe to newsletters on topics relevant to you.

Subscribe
Subscribe

Related Insights

centrifuge-machine
Life sciences & healthcare

Dissecting the Regeneron v Kymab mouse case – what it says and its impact on patents

27 July 2020
QUICK READ

by multiple authors

Click here to find out more
Life sciences & healthcare

Biosimilars – The economics of biosimilars: Market access, pricing and legal considerations

17 December 2019

by Matthew Royle, Ph.D.

Click here to find out more
Life sciences & healthcare

Recent legislative developments affecting biologics and biosimilars

30 May 2019

by multiple authors

Click here to find out more

Related events

There are no upcoming events